2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Vomiting
31
Nausea
27
Neoplasms
14
Lymphoma, Non-Hodgkin
8
Leukemia, Myeloid, Acute
7
Multiple Myeloma
6
Breast Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma
5
Burkitt Lymphoma
5
Sezary Syndrome
4
Primary Myelofibrosis
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Myeloproliferative Disorders
4
Mycosis Fungoides
4
Lymphoma, T-Cell, Cutaneous
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Leukemia, Hairy Cell
4
Hodgkin Disease
4
Uterine Cervical Neoplasms
3
Pdgfra-Associated Chronic Eosinophilic Leukemia
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Myelodysplastic Syndromes
3
Lymphoma, Large-Cell, Anaplastic
3
Interventions
Fulvestrant
3
palbociclib
2
Letrozole
2
Anastrozole
2
venetoclax
1
pyrotinib
1
pertuzumab
1
penpulimab
1
dalpiciclib
1
anlotinib
1
Tretinoin
1
Trastuzumab
1
Ropivacaine
1
Radiosurgery
1
Propofol
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Ondansetron
1
Morphine
1
Induction Chemotherapy
1
Etoricoxib
1
Docetaxel
1
Diagnostic Imaging
1
Carboplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasm Female
×
Ondansetron
×
Clear all
NCT03117894
2021-06-04
PECS-2 for Breast Surgery
Umeå University
Phase NA
Completed
200 enrolled